Meet PSI at San Antonio Breast Cancer Symposium® 2026!
PSI CRO is attending SABCS 2026 to discuss how sponsors can maintain enrollment predictability and protocol relevance in one of the most competitive oncology landscapes in clinical research.
Breast cancer development programs face constant protocol pressure as standards of care evolve during trial execution. PSI supports sponsors running complex global oncology studies with operational models designed to protect enrollment timelines, data integrity, and feasibility assumptions as the treatment landscape shifts.
In oncology, 10% of novel oncology drugs approved by the FDA since 2000 have registrational data generated through PSI-supported studies, supported by a global network of 10,000 oncology sites in 62 countries. Sponsors attending SABCS can meet with the PSI team to discuss enrollment strategy, feasibility modeling, adaptive operational planning, and site engagement approaches for breast cancer programs.
Attending team members:
- Vince Calderon
Therapeutic Area Director - Alex Goñi
Senior Director, Business Development - Anupama Acheson
Director, Medical Monitoring & Consulting - Nabila Chowdhury
Medical Monitor
Related resources:
Blog: Practice-changing progress and decisive oncology breakthroughs
Webinar: Designing pivotal ADC trials that actually enroll
White paper: Redefining feasibility in oncology
